Z
20.93
0.77 (3.82%)
| Previous Close | 20.16 |
| Open | 19.73 |
| Volume | 186,782 |
| Avg. Volume (3M) | 703,100 |
| Market Cap | 1,123,505,024 |
| Price / Earnings (TTM) | 1.53 |
| Price / Sales | 60.14 |
| Price / Book | 5.88 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Zenas BioPharma, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.6
| Analyst Consensus | -0.5 |
| Insider Activity | 1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -5.0 |
| Average | -0.60 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (Evercore ISI Group, 162.78%) | Buy |
| Median | 44.50 (112.61%) | |
| Low | 19.00 (Morgan Stanley, -9.22%) | Hold |
| Average | 40.75 (94.70%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 29.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 44.00 (110.22%) | Buy | 21.48 |
| Morgan Stanley | 06 Jan 2026 | 19.00 (-9.22%) | Hold | 15.20 |
| 13 Nov 2025 | 37.00 (76.78%) | Buy | 35.66 | |
| Wedbush | 22 Dec 2025 | 45.00 (115.00%) | Buy | 42.33 |
| Evercore ISI Group | 26 Nov 2025 | 55.00 (162.78%) | Buy | 40.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOULDER LEON O JR | 18.15 | - | 57,000 | 1,034,550 |
| Aggregate Net Quantity | 57,000 | |||
| Aggregate Net Value ($) | 1,034,550 | |||
| Aggregate Avg. Buy ($) | 18.15 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Officer | 02 Feb 2026 | Buy (+) | 57,000 | 18.15 | 1,034,550 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |